Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C30H32N6 |
| Molecular Weight | 476.6153 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)C1=CC=C(C=C1)C2=NC3=C(C=CC=C3N2)N4CCN(CC5=CC=C6N=CC=NC6=C5)CC4
InChI
InChIKey=AVEVJMZJJJDOCI-UHFFFAOYSA-N
InChI=1S/C30H32N6/c1-30(2,3)23-10-8-22(9-11-23)29-33-25-5-4-6-27(28(25)34-29)36-17-15-35(16-18-36)20-21-7-12-24-26(19-21)32-14-13-31-24/h4-14,19H,15-18,20H2,1-3H3,(H,33,34)
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.google.com.na/patents/US20060211699
Curator's Comment: description was created based on several sources, including:
http://www.google.com.na/patents/US20060211699
WAY 207024 dihydrochloride has been reported to be a potent and high affinity gonadotrophin releasing hormone receptor (GnRH-R) antagonist. WAY 207024 was assessed in vitro for broad off-target activity (65 receptors and enzymes), including the hERG potassium channel, at 2 µM. Some activity at the histamine H2, nonselective opioid, and neurokinin NK2 receptors was noted. Rats, treated orally with WAY 207024 showed profound suppression of leuteinizing hormone that lasted for up to 24 h.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
D68C48FA7B
Created by
admin on Sat Dec 16 15:20:13 GMT 2023 , Edited by admin on Sat Dec 16 15:20:13 GMT 2023
|
PRIMARY | |||
|
872002-72-7
Created by
admin on Sat Dec 16 15:20:13 GMT 2023 , Edited by admin on Sat Dec 16 15:20:13 GMT 2023
|
PRIMARY | |||
|
11496610
Created by
admin on Sat Dec 16 15:20:13 GMT 2023 , Edited by admin on Sat Dec 16 15:20:13 GMT 2023
|
PRIMARY |
![Structure of 6-[[4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl]methyl]quinoxaline](/img/fd10375e-37c9-4fe3-ab73-80b34f9ec5c3.svg "Structure of 6-[[4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl]methyl]quinoxaline")